GlassScriptPhysician profile
Aleksandra Avery
NPI 1992939409
$722.16
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $229 · 2022: $46.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $114.77 | 2019 | |
| Amgen INC. | $70.71 | 2019-2022 | |
| Lilly USA, LLC | $64.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $51.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2020 | |
| Amarin Pharma, INC. | $21.74 | 2019 | |
| Dexcom, INC. | $16.46 | 2020 | |
| Glaxosmithkline, LLC. | $14.30 | 2019 | |
| Allergan, INC. | $13.62 | 2020 | |
| Cranial Technologies, INC | $13.23 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.84 | 2022 | |
| Mylan Specialty L.P. | $11.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandra Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.